Y-Intercept (HK)’s Tarsus Pharmaceuticals TARS Stock Holding History

Y-Intercept (HK)’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.44M	Buy	54,671 +43,461	+388%	+$2.78M	0.07%	425
2026 Q1	$786K	Sell	11,210 -2,432	-18%	-$170K	0.01%	1114
2025 Q4	$1.12M	Buy	13,642 +3,168	+30%	+$237K	0.03%	932
2025 Q3	$622K	Buy	+10,474	New	+$516K	0.01%	1179
2025 Q1	–	Sell	-15,118	Closed	-$837K	–	1599
2024 Q4	$837K	Buy	+15,118	New	+$687K	0.06%	498

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Y-Intercept (HK)'s TARS Position: Q2 2026 in Review

Y-Intercept (HK) increased its Tarsus Pharmaceuticals (TARS) stake by 388% in Q2 2026, buying an estimated $2.78M and bringing the position to 54,671 shares worth $3.44M. The position accounts for 0.07% of the portfolio, ranked #425.

Y-Intercept (HK) first reported a position in TARS in Q4 2024 and has held it in 5 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Y-Intercept (HK) held 54,671 shares of Tarsus Pharmaceuticals worth $3.44M as of Q2 2026.
Y-Intercept (HK) bought 43,461 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $2.78M.
Tarsus Pharmaceuticals made up 0.07% of Y-Intercept (HK)'s portfolio in Q2 2026, its #425 holding.
Y-Intercept (HK) first reported a position in Tarsus Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.